Substituted bicyclic compounds as farnesoid X receptor modulators

US12227496B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Dean A. Wacker · Chadds Ford, US
• Susheel Jethanand Nara · Mumbai, IN
• Srinivas Cheruku · Bengaluru, IN
• Kandhasamy Sarkunam · Hosur, IN
• Firoz Jaipuri · Bengaluru, IN
• Rishikesh Narayan · Mumbai, IN
• Subba Reddy Bandreddy · Kanchinakote, IN
• Srinivas Jogi · Kanchinakote, IN

Key dates

• Filing date: Feb 14, 2020
• Grant date: Feb 18, 2025
• Expiry date: Mar 6, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/14
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Disclosed are compounds of Formula (I): or a stereoisomer, a tautomer, or a salt or solvate thereof, wherein Q is C2-6 alkenyl or C2-6 alkynyl, each substituted with zero to 2 R1; and the other variables are as defined herein. These compounds modulate the activity of farnesoid X receptor (FXR), for example, as agonists. Also disclosed are pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.